Posted by Michael Wonder on 11 Apr 2026
FDA approves updated Vabysmo label to extend treatment for macular oedema following retinal vein occlusion beyond six months
9 April 2026 - Genentech has received US FDA approval of Vabysmo (faricimab-svoa) for the treatment of macular oedema due to retinal vein occlusion beyond six months.
Retinal vein occlusion affects over a million Americans and often involves long-term intravitreal therapy to address the chronic nature of the disease.
